Antimicrobial activity of Obioactin.
A newly developed enzyme-hydrolyzed toxoplasma-hyperimmune bovine serum preparation, Obioactin , was examined for its anti-microbial and related actions against heterologous protozoa, bacteria, and viruses both in-vivo and in-vitro. An appreciable efficacy of Obioactin in a combination with nifurtimox, Lampit was observed in experimental Trypanosoma cruzi infections in mice. But prophylactic applications of the agent alone or joint with Lampit were in vain in mice. In-vitro digestion of certain bacteria in mouse peritoneal macrophages was accelerated in the presence of the agent being three to ten times stronger than that in untreated macrophages. Inhibitory effect of Obioactin on in-vitro infectivity of viruses was suggested.
D000818:Animals; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D014355:Chagas Disease / Q000188:drug therapy / Q000401:mortality; D002646:Chikungunya virus / Q000187:drug effects; D006224:Cricetinae; D004359:Drug Therapy, Combination; D004664:Encephalitis Virus, Japanese / Q000187:drug effects; D005260:Female; D006801:Humans; D007136:Immunoglobulins; D008088:Listeriosis / Q000188:drug therapy; D008264:Macrophages / Q000276:immunology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009547:Nifurtimox / Q000627:therapeutic use; D010587:Phagocytosis / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D018139:Simplexvirus / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007136:Immunoglobulins; C041544:obioactin; D009547:Nifurtimox